Remove Biopharma Remove Leads Remove Medical science
article thumbnail

Amgen and Pfizer appoint new Science executives

European Pharmaceutical Review

Prior to his work in the biopharma industry, Dr Boshoff was founding Director of the University College London (UCL) Cancer Institute. He earned his medical degree from University of Pretoria in South Africa, a doctorate PhD from the Institute of Cancer Research in London. Academy of Medical Sciences. “I

article thumbnail

7 commercial, sales, and marketing predictions for 2023

pharmaphorum

With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance. Leading companies will empower their teams to act quickly, compliantly, and with a unified view of the HCP.”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. sales, medical science liaisons, etc.).

article thumbnail

Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

Medgadget

Thanks to kind support from Biomed Israel , the leading international Life Science and HealthTech conference in Israel (see more below), we met with Ronan Castro, the CEO of Human Xtensions at the company’s offices in Netanya, Israel. More info can be found at the Biomed Israel website.

article thumbnail

Alpha TAU Killing Tumors With Highly Targeted Alpha Radiation

Medgadget

This leads to substantial damage to healthy tissues and too often results in poor outcomes. This will hopefully lead to an FDA approval for its first indication, after which Alpha TAU plans on expanding to other types of cancer and geographic regions such as Europe and Japan. which are currently recruiting patients.